Form D Don’t Lie: Chronix Biomedical $5.01 million Fundraising. John DiPietro Published Oct 31 D Filing

Biotechnology Chronix Biomedical Inc - John DiPietro

Chronix Biomedical Financing

Chronix Biomedical Inc, Corporation just released form D regarding $5.01 million equity financing. This is a new filing. Chronix Biomedical was able to sell $5.01 million. That is 100.00% of the fundraising offer. The total financing amount was $5.01 million. The financing form was filed on 2016-10-31. The reason for the financing was: unspecified.

Chronix Biomedical is based in California. The company’s business is Biotechnology. The form D was signed by John DiPietro Chief Financial Officer. The company was incorporated more than five years ago. The filler’s address is: 5941 Optical Court, Suite 203E, San Jose, Ca, California, 95138. John Dipietro is the related person in the form and it has address: 5941 Optical Court, Suite 203E, San Jose, Ca, California, 95138. Link to Chronix Biomedical Filing: 000112911616000001.

Analysis of Chronix Biomedical Offering

On average, firms in the Biotechnology sector, sell 73.77% of the total offering size. Chronix Biomedical sold 100.00% of the offering. Could this mean that the trust in Chronix Biomedical is high? The average investment offering size for companies in the Biotechnology industry is $3.08 million. The total amount raised is 62.75% bigger than the average for companies in the Biotechnology sector. The minimum investment for this offering was set at $5000. If you know more about the reasons for the financing, please comment below.

What is Form D? What It Is Used For

Form D disclosures could be used to track and understand better your competitors. The information in Form D is usually highly confidential for ventures and startups and they don’t like revealing it. This is because it reveals amount raised or planned to be raised as well as reasons for the financing. This could help competitors. Entrepreneurs usually want to keep their financing a ‘secret’ so they can stay in stealth mode for longer.

Why Fundraising Reporting Is Good For Chronix Biomedical Also

The Form D signed by John DiPietro might help Chronix Biomedical Inc’s sector. First, it helps potential customers feel more safe to deal with a firm that is well financed. The odds are higher that it will stay in the business. Second, this could attract other investors such as venture-capital firms, funds and angels. Third, positive PR effects could even bring leasing firms and venture lenders.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment